← All indications
Crohn Disease
A chronic transmural inflammation that may involve any part of the DIGESTIVE TRACT from MOUTH to ANUS, mostly found in the ILEUM, the CECUM, and the COLON. In Crohn disease, the inflammation, extending through the intestinal wall from the MUCOSA to the serosa, is characteristically asymmetric and segmental. Epithelioid GRANULOMAS may be seen in some patients.
Drugs by status
Approved for this indication (15)
Phase 4 trials (70)
- metronidazole
- 23-valent pneumococcal polysaccharide vaccine
- vitamin d3
- mercaptopurine
- procaine benzylpenicillin
- bisacodyl
- colesevelam
- clofazimine
- golimumab
- doxycycline
- betamethasone
- epaxal
- naltrexone
- soybean oil
- esketamine
- linaclotide
- mirikizumab
- adalimumab
- pneumococcal 13-valent conjugate vaccine
- posaconazole
- caffeine
- prucalopride succinate
- epinephrine
- rifabutin
- risankizumab
- celecoxib
- sirolimus
- risedronate
- sulfur hexafluoride lipid-type a microspheres
- bupivacaine
- +40 more
Phase 3 trials (51)
- ringer's lactate
- thalidomide
- azacitidine
- alicaforsen
- beta carotene
- cannabidiol
- etrolizumab
- ferric carboxymaltose
- ferric maltol
- filgotinib
- mongersen
- somatropin
- guselkumab
- bone marrow derived mesenchymal stem cells
- mecasermin
- iron dextran
- omega-3-carboxylic acids
- rifaximin
- ozanimod
- acetylsalicylic acid
- cyclophosphamide
- abatacept
- tetomilast
- mesalazine
- fluconazole
- tripterygium wilfordii
- zoledronic acid
- allogeneic adipose derived mesenchymal stem cell
- agaricus blazei murill
- umbilical cord mesenchymal stem cells
- +21 more
Phase 2 trials (141)
- aminosalicylic acid
- iron
- xanthohumol
- denosumab
- pf-00547659
- 99mtc ec20
- abt-981
- obefazimod
- secukinumab
- colon extract
- vitamin e
- brodalumab
- aminolevulinic acid
- Andecaliximab
- anti-interferon-gamma monoclonal antibody
- bay94-9392
- beta-hydroxybutyrate
- bli-1300
- bms-936557
- briakinumab
- lenalidomide
- chondroitin
- clazakizumab
- clofarabine
- diphenhydramine
- osi-461
- tofacitinib
- da jian zhong tang
- dehydroepiandrosterone
- dlx105
- +111 more
Phase 1 trials (37)
- maltodextrin
- calcium carbonate
- cranberry
- empagliflozin
- prinaberel
- l-glutamine
- hemopoietic stem cell
- lactulose
- rosuvastatin
- warfarin
- nivolumab
- whey protein
- mb-102
- autologous dendritic cells
- pentoxifylline
- verapamil
- AMG220
- chadox2 hav
- fibroblast
- microbiota
- mdgn-002
- msc-afp
- cenplacel-l
- bovine immunoglobin
- apixaban
- rhamnose
- exametazime
- menadiol
- ubiquinone
- foralumab
- +7 more
Other trials (26)
Organizations
Organization Involved with Phase 4 Indications (120)
- Abbott
- AbbVie
- Millennium Pharmaceuticals
- Centocor
- Elan Pharmaceuticals
- Pfizer
- Biogen
- Orphan Australia
- Fundación Pública Andaluza
- PIBD-Net
- ZonMw: The Netherlands Organisation for Health Research and Development
- University of Roma La Sapienza
- Maastricht University
- University of Pittsburgh
- Atlanta Gastroenterology Associates
- Belgian IBD Research Group
- Boston University
- Cedars-Sinai Medical Center
- University of London
- Harvard University
- Diakonhjemmet Hospital
- Federal University of Juiz de Fora
- Georgetown University
- Hoosier Cancer Research Network
- Hospital General Universitario Gregorio Marañon
- Inje University
- Institut National de la Santé Et de la Recherche Médicale, France
- Korea University
- Kosin University
- Kyung Hee University
- +90 more
Organization Involved with Phase 3 Indications (106)
- PPD
- Eisai
- Celgene
- Shire
- Tercica
- Bristol-Myers Squibb
- Galapagos NV
- Bausch Health Companies
- Roche
- Gilead Sciences
- Eli Lilly
- Tillotts Pharma
- Genzyme
- Grifols
- Perrigo
- Allergan
- Cellerix
- Celltrion
- Effice Servicios Para la Investigacion S.L.
- Erydel
- GlaxoSmithKline
- Ionis Pharmaceuticals, Inc.
- Parexel
- Pileje
- Shield Therapeutics
- Vifor Inc.
- Boehringer Ingelheim
- Otsuka
- TiGenix
- VSL Pharmaceuticals
- +76 more
Organization Involved with Phase 2 Indications (109)
- Abivax S.A.
- Jacobus Pharmaceutical
- Facet Biotech
- Theravance
- Amgen
- OSI Pharmaceuticals
- Astellas
- Merck Serono
- Novo Nordisk
- Genentech
- PDL BioPharma
- Romark
- Wyeth
- Novartis
- Arena Pharmaceuticals
- Braintree Laboratories
- ChemoCentryx
- Delenex Therapeutics AG
- Fast Forward Pharmaceuticals
- Endocyte
- INC Research
- Inflabloc Pharmaceuticals
- Italfarmaco
- Kang Stem Biotech Co., Ltd.
- Mallinckrodt
- NPS Pharma
- Neovacs
- NovImmune SA
- R&R Inc.
- Synta Pharmaceuticals Corp.
- +79 more
Organization Involved with Phase 1 Indications (20)
- Avidia
- Fresenius
- Aevi Genomic Medicine
- Anterogen Co., Ltd.
- MediBeacon
- Enterome
- Seattle Children's Hospital
- Monash University
- Royan Institute
- University of Miami
- Stony Brook University
- Wenzhou Medical University
- All India Institute of Medical Sciences
- Alliance Foundation Trials
- University of Queensland
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Oxford
- University of Texas at Houston
- Nutrition Science Partners Limited
- Atlanta Clinical and Translational Science Institute
Organization Involved with Other Experimental Indications (34)
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Anhui Medical University
- Hillel Yaffe Medical Center
- Indiana University
- Texas A&M University
- University of Dundee
- University of Louisville
- University of Ottawa
- University of Tampere
- Utrecht University
- University of Bologna
- University of Vermont
- University of Virginia
- University of Turku
- Leiden University
- University of Campinas
- Klinikum Westbrandenburg
- Government of Russia
- Friedrich Schiller University
- Government of China
- Kuopio University Hospital
- Charles University
- University of Perugia
- Department of Veteran Affairs
- German Federal Ministry of Education and Research
- Canadian Association of Gastroenterology
- NASPGHAN Foundation
- American College of Gastroenterology
- Government of Finland
- Iscare i.v.f., Czech Republic
- +4 more